PT-141 (Bremelanotide)

Melanocortin (libido, tanning, appetite)FDA-approved (women's low desire)

Also known as: Vyleesi

A melanocortin agonist that increases sexual desire through the brain rather than blood flow.

Educational reference, not medical advice. Many compounds here are not approved, and products sold as research chemicals are not checked for purity. Plan any use with a licensed clinician.

How it works

Activates MC4 receptors in the hypothalamus, which drive desire and arousal.

Evidence by goal

GoalGradeWhat the grade means
Libido & sexual functionAApproved for this use or large randomized trials

At a glance

Route
Subcutaneous, as needed
Half-life
About 2.7 hours

Reported dosing

Label: 1.75 mg SC, no more than 1 dose per 24 hours and 8 per month.

Timing: At least 45 minutes before sexual activity.

Cycle: As needed only.

From approved labels where they exist, otherwise from published trials and practitioner reports.

Side effects

  • Nausea (about 40% at first dose)
  • Flushing, headache
  • Temporary rise in blood pressure
  • Darkening of skin patches with frequent use

Who should avoid it

  • Uncontrolled high blood pressure
  • Heart disease

Often combined with

Do not combine with Melanotan II.

Key findings

Approved for premenopausal women with low desire (HSDD). Trials in men with erectile dysfunction showed effect but were not pursued.

Where it is legal (Oct 2026)

USPrescription
CanadaNot approved
MexicoNot approved
EUNot approved

Sources

Open PT-141 (Bremelanotide) in the Peptide Guide Compare all peptides by goal

Last reviewed November 2026. Regulatory status reflects the US unless noted and changes often.

Natoorales and e4life.io (Mexico residency and immigration help) are sister businesses founded by Ian Kain.

Scroll to Top